Emodin alleviates chronic constriction injury-induced neuropathic pain and inflammation via modulating PPAR-gamma pathway

This study investigates the potential of Emodin, a natural compound, to alleviate neuropathic pain (NP) caused by chronic constriction injury (CCI) in rats. Neuropathic pain is a chronic condition resulting from damage to the sensorimotor system and is often difficult to treat. The researchers examined Emodin's impact on pain sensitivity, inflammation, and oxidative stress in rats with CCI. They also explored the involvement of the PPAR-γ pathway, a key regulator of inflammation and metabolism, in Emodin's therapeutic effects. The findings suggest that Emodin has antinociceptive and anti-hyperalgesic properties, reducing pain perception and inflammation. The study proposes that Emodin's therapeutic potential in chronic nerve injury involves the PPAR-γ pathway.

• 1
  Emodin elevated response latency and delayed the onset of mechanical hyperalgesia in rats with CCI on days 7, 14, and 21.
• 2
  Emodin treatment significantly reduced lipid peroxidation and NO levels, while restoring GST, GSH, and catalase.
• 3
  Emodin significantly improved the disorientation of the sciatic nerve and spinal cord and reduced inflammatory markers.